skip to main content
Banner Image

Cardiovascular research

Cardiovascular Research

The pace of advancements in understanding cardiovascular disease (CVD) — based on the translation of basic and clinical research findings into prevention, treatment and rehabilitation — continues to accelerate rapidly in ways once relegated to fantasy. Biomedical studies and clinical trials investigating the diseases of the heart and vascular system have had a profound impact on the lives of countless individuals.

  • More Americans die annually of CVD than cancer, accidents and HIV (AIDS) combined.
  • Over 81 million Americans have one or more forms of CVD, including hypertension, coronary heart disease, stroke and heart failure.
  • Vascular injuries begin in adolescence, making primary prevention efforts vital from childhood.
  • Some areas currently being researched include the link between inflammation and atherosclerosis.
  • Cardiovascular disease is the most common cause of death in people with diabetes.

Source: American Heart Association

A leading cardiac center, NYU Winthrop Hospital is recognized throughout New York State for achieving exemplary patient outcomes. Leaders in their field, the Hospital’s cardiac specialists develop, participate in and lead numerous research studies to evaluate the newest medications and develop advanced interventional devices. They study mechanisms that make people with diabetes and lupus erythematosis at high risk for atherosclerosis. NYU Winthrop researchers have identified new information on the link between anti-inflammatory drugs and cardiovascular risk.

WUH Researchers’ Study:

  • Effects of angioplasty in diabetic patients with multi-vessel disease
  • comparisons of angioplasty with or without percutaneous ventricular assist device placement
  • Optimal duration of anti-platelet therapy after stent placement.
  • Insulin’s effect on smooth muscle contraction
  • Effects of prostaglandins on vascular smooth muscle cell proliferation, migration and apoptosis
  • The mechanisms underlying the increased risk for developing cardiovascular disease seen in persons with the autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus
  • Mechanisms linking cyclo-oxygenase (COX) inhibitors to increased risk of cardiovascular disease.
  • Therapeutic strategies to prevent and treat the accelerated atherosclerosis that occurs in rheumatic diseases and with prolonged use of COX inhibitors.
  • Effects of mesenchymal cell functions in major vessels.